Salvanou Evangelia-Alexandra, Apostolopoulou Adamantia, Xanthopoulos Stavros, Koelewijn Stuart, van Overeem Philippe, Laurent Gautier, Bazzi Rana, Denat Franck, Roux Stéphane, Bouziotis Penelope
Radiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Patriarchou Grigoriou and 27 Neapoleos Street, 15341 Athens, Greece.
Terthera b.v., Minervum 7070, 4817 ZK Breda, The Netherlands.
Materials (Basel). 2025 Jan 8;18(2):248. doi: 10.3390/ma18020248.
Due to their intriguing emission profile, Terbium-161 (Tb) radiopharmaceuticals seem to bring significant advancement in theranostic applications to cancer treatment. The combination of Tb with nanoscale brachytherapy as an approach for cancer treatment is particularly advantageous and promising. Herein, we propose the application of a hybrid nanosystem comprising gold decorated (Au@TADOTAGA) iron oxide nanoflowers as a form of injectable nanobrachytherapy for the local treatment of breast cancer. More specifically, Au@TADOTAGA and NFAu@TADOTAGA NPs were efficiently radiolabeled with Tb, and their in vitro stability was assessed up to 21 d post-radiolabeling. Furthermore, their cytotoxic profile against 4T1 breast cancer cells was evaluated, and their ex vivo biodistribution characteristics were revealed after intratumoral injection in the same animal model. The enhanced retention at the tumor site urged us to evaluate the therapeutic effect of the [Tb]Tb-NFAu@TADOTAGA nanosystem after intratumoral administration to 4T1-tumor-bearing mice, over a period of 24 days. Three different therapeutic protocols were performed in order to identify which therapeutic approach would offer the optimum results and identify the proposed nanosystem as a promising nanoscale brachytherapy agent.
由于其引人入胜的发射特性，铽-161（Tb）放射性药物似乎在癌症治疗的诊疗应用中带来了重大进展。将Tb与纳米级近距离放射疗法相结合作为一种癌症治疗方法特别具有优势且前景广阔。在此，我们提出应用一种包含金修饰（Au@TADOTAGA）的氧化铁纳米花的混合纳米系统，作为一种可注射纳米近距离放射疗法用于乳腺癌的局部治疗。更具体地说，Au@TADOTAGA和NFAu@TADOTAGA纳米颗粒用Tb进行了高效放射性标记，并在放射性标记后长达21天评估了它们的体外稳定性。此外，评估了它们对4T1乳腺癌细胞的细胞毒性，并且在同一动物模型中瘤内注射后揭示了它们的体内生物分布特征。在肿瘤部位的增强滞留促使我们评估[Tb]Tb-NFAu@TADOTAGA纳米系统在对荷4T1肿瘤小鼠进行瘤内给药后24天内的治疗效果。进行了三种不同的治疗方案，以确定哪种治疗方法能提供最佳结果，并将所提出的纳米系统鉴定为一种有前景的纳米级近距离放射治疗剂。
